Conference abstract · 12 Nov 2013
Conference abstractPublished 12 Nov 2013
CAPA and risk management
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The pharmaceutical company should have a system for implementing corrective actions and preventive actions resulting from the; investigation of complaints, Product rejections, Non- conformances, Recalls, deviations, Audits, Regulatory inspections and findings, and Trends from process performance and product quality monitoring. A structured approach to the investigation process should be used with the objective of determining the root cause. The level of effort, formality, and documentation of the investigation should be commensurate with the level of risk, In line with ICH Q9 ?Quality Risk Management?. CAPA methodology should result in product and process improvements and enhanced product and process understanding. Corrective Action: Corrective action is aiming to correct an existing non-conformity and to avoid reoccurrence of the same nonconformity. Corrective action may arise, from manufacturing deviations, OOS investigations, complaints, audit findings, recalls. A systematic investigation should be performed to determine the reason(s) for the non-conformities and to agree upon appropriate corrective action. All Agreed corrective actions should be closely followed-up and monitored till completion. Management should be notified about the costs and impact of failure including the respective corrective actions. Preventive Action: Preventive action should be aiming to avoid the initial occurrence of non-conformity by proactively implementing improvements. Preventive action may result from trending of in process data, of analytical data, of audit findings, Trending of root causes for non-conformities or complaints, From product quality reviews (annual product reviews), Quality risk analyses, etc. Similar to corrective actions, All Agreed Preventive Actions should be closely followed-up and monitored till their completion. Effectiveness of preventive actions should be reviewed regularly, as part of the product quality review (annual product review). Effective CAPA Process, CAPA Challenges & CAPA Management Software are the key factors
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 8 Sep 2014
CAPA program management via the DMAIC methodology
Article · 19 Jun 2026
Enhancing Medicine Safety Through Effective Risk Management Strategies
Article · 12 Mar 2026
Structured Approaches in Pharmaceutical Risk Management for Patient Safety
Article · 12 Mar 2026
Integration of Pharmacovigilance and Risk Management in Modern Medicine Safety Systems
More from this journal
The newest in Journal of Developing Drugs.
Research article · 17 Jul 2026
Effects of a Food-Derived GLP-1 Formula on Endogenous GLP-1 Secretion and Appetite Responses: A Randomized Double-Blind Crossover Study
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Rucha Majmundar Mehta”

